Last reviewed · How we verify
SGLT2 Inhibition
SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | SGLT2 Inhibition |
|---|---|
| Also known as | Dapagliflozine,Empagliflozin,Canagliflozin |
| Sponsor | Zhongshan Hospital Xiamen University |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (Sodium-Glucose Cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 inhibitors work by inhibiting the SGLT2 transporter protein located in the proximal tubule of the kidney. This prevents the reabsorption of filtered glucose, leading to increased urinary glucose excretion (glucosuria) and lowering of blood glucose levels. Beyond glycemic control, these agents provide cardiovascular and renal protective effects through mechanisms including osmotic diuresis, improved insulin sensitivity, and reduced intraglomerular pressure.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Diabetic ketoacidosis
- Volume depletion
Key clinical trials
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- SGLT2 Inhibition in Hemodialysis (PHASE2)
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (PHASE3)
- CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients (PHASE2)
- Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
- Empagliflozin Reversal of Arterial StiffnEss in Aging (PHASE2, PHASE3)
- Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (PHASE2)
- SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGLT2 Inhibition CI brief — competitive landscape report
- SGLT2 Inhibition updates RSS · CI watch RSS
- Zhongshan Hospital Xiamen University portfolio CI